Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. (Q54325796)

27 May 2018

title

Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. (English)

1 reference

27 May 2018

1 reference

Tadayasu Togawa

1

1 reference

27 May 2018

Takahiro Tsukimura

2

1 reference

27 May 2018

Takashi Kodama

3

1 reference

27 May 2018

Toshie Tanaka

4

1 reference

27 May 2018

Ikuo Kawashima

5

1 reference

27 May 2018

Seiji Saito

6

1 reference

27 May 2018

Kazuki Ohno

7

1 reference

27 May 2018

Tomoko Fukushige

8

1 reference

27 May 2018

Takuro Kanekura

9

1 reference

27 May 2018

Atsushi Satomura

10

1 reference

27 May 2018

Duk-Hee Kang

11

1 reference

27 May 2018

Beom Hee Lee

12

1 reference

27 May 2018

Han-Wook Yoo

13

1 reference

27 May 2018

Kent Doi

14

1 reference

27 May 2018

Eisei Noiri

15

1 reference

27 May 2018

Hitoshi Sakuraba

16

1 reference

27 May 2018

publication date

18 January 2012

1 reference

27 May 2018

Molecular Genetics and Metabolism

published in

1 reference

27 May 2018

volume

105

1 reference

27 May 2018

page(s)

615-620

1 reference

27 May 2018

issue

4

1 reference

27 May 2018

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

High incidence of later-onset fabry disease revealed by newborn screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Significance of screening for Fabry disease among male dialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Plasma globotriaosylsphingosine as a biomarker of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Algorithms for calculating excluded volume and its derivatives as a function of molecular conformation and their use in energy minimization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Accurate modeling of the intramolecular electrostatic energy of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Calculation of the reaction field due to off-center point multipoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Molecular and structural studies of the GM2 gangliosidosis 0 variant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Structural characterization of mutant alpha-galactosidases causing Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Point mutations in the upstream region of the ?-galactosidase A gene exon 6 in an atypical variant of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.01.010

10.1016/J.YMGME.2012.01.010

7 January 2021

Identifiers

DOI

1 reference

27 May 2018

PubMed ID

22305854

1 reference

27 May 2018